ID 60788
FullText URL
fulltext.pdf 2.07 MB
Author
Xu, Naijin Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Lin, Wenfeng Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sun, Jingkai Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sadahira, Takuya Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Xu, Abai Department of Urology, Zhujiang Hospital, Southern Medical University
Watanabe, Masami Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons researchmap
Guo, Kai Department of Urology, Zhujiang Hospital, Southern Medical University
Araki, Motoo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Li, Gonghui Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Liu, Chunxiao Department of Urology, Zhujiang Hospital, Southern Medical University
Nasu, Yasutomo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons researchmap
Huang, Peng Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Abstract
Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has been found to be effective against several cancers. However, few studies have examined the anti-tumor activity of nitroxoline in bladder cancer. The purpose of the study was to reveal the possible mechanisms how nitroxoline inhibited bladder cancer progression. In vitro assay, we demonstrated that nitroxoline inhibited bladder cancer cell growth and migration in a concentration-related manner. Western blot analysis demonstrated that nitroxoline downregulated the expressions of epithelial mesenchymal transition (EMT)-related proteins. Furthermore, treatment with nitroxoline in the C3H/He mice bladder cancer subcutaneous model resulted in significant inhibition of tumor growth. Moreover, the percentage of myeloid-derived suppressor cells (MDSC) in peripheral blood cells significantly decreased after treatment of nitroxoline. Taken together, our results suggested that nitroxoline may be used as a potential drug for bladder cancer.
Keywords
Nitroxoline
Bladder cancer
EMT
immunotherapy preclinical model
Published Date
2020-09-23
Publication Title
Journal of Cancer
Volume
volume11
Issue
issue22
Publisher
Ivyspring International Publisher
Start Page
6633
End Page
6641
ISSN
1837-9664
Content Type
Journal Article
language
英語
OAI-PMH Set
岡山大学
Copyright Holders
© The author(s).
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.7150/jca.47025
License
https://creativecommons.org/licenses/by/4.0/
Funder Name
Ministry of Education, Culture, Sports, Science and Technology
助成番号
17K11138